Want to see HAE full AI Analyst Report?
Operating Income by Segment
Shows profit generated by each business unit, highlighting which segments contribute the most to the company’s bottom line and which consume investment. Helps investors see whether Haemonetics’ core operations are profitable, where margin improvement is possible, and how strategic choices or cost pressures affect overall earnings.Plasma and Hospital were the engines of margin expansion through 2022–early‑2024 but hit a pronounced mid‑2024 reset from portfolio transitions, tariffs and the absence of a prior CSL payment; plasma has partially recovered but not to prior peaks, while hospitals show steadier rebound driven by mix and new product rollouts. Blood Center reflects a structural decline after the whole‑blood divestiture. Management’s FY27 margin thesis depends on plasma innovation and hospital mix; volatile corporate costs (tariffs, ERP, Vivasure dilution) are the main execution risk.
Date | Corporate & Other | Plasma | Blood Center | Medsurg | Apheresis |
|---|---|---|---|---|---|
Jun 30, 2026 | -$21.80M | $0.00 | $0.00 | $22.71M | $56.55M |
Mar 31, 2026 | -$86.80M | $43.70M | $11.20M | $29.60M | $0.00 |
Dec 31, 2025 | -$21.78M | $50.23M | $13.03M | $25.92M | $0.00 |
Sep 30, 2025 | -$28.79M | $42.59M | $14.82M | $29.86M | $0.00 |
Jun 30, 2025 | -$23.68M | $48.28M | $10.89M | $18.38M | $0.00 |
Mar 31, 2025 | -$11.01M | $50.63M | $9.91M | $21.79M | $0.00 |
Dec 31, 2024 | -$30.41M | $47.73M | $14.32M | $27.39M | $0.00 |
Sep 30, 2024 | -$31.81M | $44.43M | $15.80M | $23.28M | $0.00 |
Jun 30, 2024 | -$31.27M | $41.72M | $12.78M | $16.52M | $0.00 |
Mar 31, 2024 | -$126.02M | $75.60M | $28.31M | $52.05M | $0.00 |